ATE346301T1 - Diagnose von krebsstadium oder aggressivität - Google Patents

Diagnose von krebsstadium oder aggressivität

Info

Publication number
ATE346301T1
ATE346301T1 AT99960625T AT99960625T ATE346301T1 AT E346301 T1 ATE346301 T1 AT E346301T1 AT 99960625 T AT99960625 T AT 99960625T AT 99960625 T AT99960625 T AT 99960625T AT E346301 T1 ATE346301 T1 AT E346301T1
Authority
AT
Austria
Prior art keywords
cancer
aggressiveness
stage
fatty acid
acid binding
Prior art date
Application number
AT99960625T
Other languages
English (en)
Inventor
Marti Jett
Rina Das
Roger Neill
Original Assignee
Wrair Walter Reed Army Inst Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrair Walter Reed Army Inst Of filed Critical Wrair Walter Reed Army Inst Of
Application granted granted Critical
Publication of ATE346301T1 publication Critical patent/ATE346301T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99960625T 1998-12-01 1999-11-30 Diagnose von krebsstadium oder aggressivität ATE346301T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11048498P 1998-12-01 1998-12-01

Publications (1)

Publication Number Publication Date
ATE346301T1 true ATE346301T1 (de) 2006-12-15

Family

ID=22333265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960625T ATE346301T1 (de) 1998-12-01 1999-11-30 Diagnose von krebsstadium oder aggressivität

Country Status (7)

Country Link
US (1) US7175981B2 (de)
EP (1) EP1135686B1 (de)
AT (1) ATE346301T1 (de)
AU (1) AU768734B2 (de)
CA (1) CA2353546C (de)
DE (1) DE69934139D1 (de)
WO (1) WO2000033083A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815517B2 (en) * 1999-12-28 2014-08-26 Ribonomics, Inc. Methods for identifying functionally related genes and drug targets
JP5002105B2 (ja) * 1999-12-28 2012-08-15 リボノミックス， インコーポレイテッド 内因性のｍＲＮＡタンパク質（ｍＲＮＰ）複合体の単離および特徴付けの方法
WO2005015220A1 (en) * 2003-08-04 2005-02-17 Roche Diagnostics Gmbh Use of protein crabp-i as a marker for breast cancer
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
DE102005026710A1 (de) * 2005-06-09 2006-12-14 Basf Ag Verfahren zum Testen von Substanzen oder Substanzgemischen, dessen Verwendung und entsprechende Analysekits
US7799519B2 (en) * 2005-07-07 2010-09-21 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
GB0604370D0 (en) * 2006-03-03 2006-04-12 Univ Dublin Markers for melanoma progression
ES2494845T3 (es) * 2006-03-22 2014-09-16 Ds Pharma Biomedical Co., Ltd. Diagnosis de enteritis aguda por determinación en sangre de la proteína intestinal de unión a ácidos grasos
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
WO2009019368A2 (fr) * 2007-07-19 2009-02-12 bioMérieux Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
WO2009156584A1 (en) * 2008-06-24 2009-12-30 Valtion Teknillinen Tutkimuskeskus Assessing risk of metastases and/or ddfs of patients with neoplasms, screening of patients responding to cancer therapy and such therapy
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2013163431A1 (en) * 2012-04-25 2013-10-31 Sanford-Burnham Medical Research Institute Diagnosis and treatment of brain tumor
FR3001806B1 (fr) 2013-02-01 2016-05-20 Biomerieux Sa Procede de detection d'une lesion colorectale
EP3479124B1 (de) * 2016-06-30 2025-04-02 Randox Laboratories Ltd Messung von fabp zur diagnose
EP3273240A1 (de) 2016-07-17 2018-01-24 Mitogro OÜ Verfahren zur auswahl von patienten mit reaktion auf krebsbehandlungen
JP6581274B1 (ja) * 2018-09-28 2019-09-25 シミックホールディングス株式会社 肝疾患の検査方法、その検査キット及びコンパニオン診断薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2245374B1 (de) 1973-07-27 1977-02-25 Anvar
US4547367A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis B core antigen vaccine

Also Published As

Publication number Publication date
DE69934139D1 (de) 2007-01-04
AU768734B2 (en) 2004-01-08
WO2000033083A1 (en) 2000-06-08
EP1135686B1 (de) 2006-11-22
EP1135686A1 (de) 2001-09-26
CA2353546A1 (en) 2000-06-08
CA2353546C (en) 2009-05-19
US7175981B2 (en) 2007-02-13
AU1748300A (en) 2000-06-19
US20020127619A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ATE346301T1 (de) Diagnose von krebsstadium oder aggressivität
ATE302278T1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
Go et al. Disturbed flow enhances inflammatory signaling and atherogenesis by increasing thioredoxin-1 level in endothelial cell nuclei
CN103743904B (zh) 一种用于微浸润性肺腺癌的双标免疫组化染色试剂盒
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
Yaskevich et al. Anxiety-depressive disorders in elderly migrants of the far north in the period of readaptation to new climatic conditions
Pavićević et al. Binding of doxyl stearic spin labels to human serum albumin: an EPR study
Kobayashi et al. Type I collagen metabolites as tumor markers in patients with lung carcinoma
DE69935905D1 (de) Fettsäure transportproteine
Beninati et al. An overview of the first 50 years of transglutaminase research
Sherwin et al. Altered LDH isozymes in brain tumors
Fedele et al. Prognostic relationship of metabolic profile obtained of melanoma B16F10
Morales-González¹ et al. Nrf2 modulates cell proliferation and antioxidants defenses during liver regeneration induced by partial hepatectomy
Aksoy et al. Dynamic thiol/disulphide homeostasis in vitiligo patients
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
Kuliszkiewicz‐Janus et al. Chemotherapy‐associated changes in 31P MRS spectra of sera from patients with multiple myeloma
Badea et al. Structural heterogenity of intraluminal content of the prostate: a histochemical and ultrastructural study
EP1601682A4 (de) Verbindungen und verfahren zur diagnose und behandlung von prostatakrebs
RU2207573C2 (ru) Способ прогнозирования продолжительности жизни больных печеночно-клеточной карциномой
Nishida et al. Sentinel lymph node biopsy reveals a positive popliteal node in clear cell sarcoma
Khvorykh et al. The comparison of searching strategies for genes related to is-chemic stroke: case-control Human and model animal studies
Samaha Human striated muscle myofibrils and actomyosin
Koduru et al. Indicators of oxidative stress in thyroid cancer
Thambiah et al. A pilot study on pattern B lipoprotein profile in Malaysia
Frimpong et al. Anatomic locations and metastatic risk in prostate cancer in african men: insights from an African cohort

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties